ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Amylyx Pharmaceuticals, Inc. (AMLX) stock surged +4.83%, trading at $3.91 on NASDAQ, up from the previous close of $3.73. The stock opened at $3.82, fluctuating between $3.73 and $4.10 in the recent session.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Employees | 384 |
Beta | -0.51 |
Sales or Revenue | $380.79M |
5Y Sales Change% | 223.262% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |